Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1<sup>−/−</sup> Mice

Mismatch repair deficient (MMR-D) tumors exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, plenty of neo-antigens are present on the tumor cells&#8217; surface, ideally shared among different cancer types. The MLH1 knock out mouse represents a preclinical model t...

Full description

Bibliographic Details
Main Authors: Yvonne Saara Gladbach, Leonie Wiegele, Mohamed Hamed, Anna-Marie Merkenschläger, Georg Fuellen, Christian Junghanss, Claudia Maletzki
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/10/1485
Description
Summary:Mismatch repair deficient (MMR-D) tumors exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, plenty of neo-antigens are present on the tumor cells&#8217; surface, ideally shared among different cancer types. The MLH1 knock out mouse represents a preclinical model that resembles features of the human MMR-D counterpart. While these mice develop neoplasias in a sequential twin-peaked manner (lymphomas &gt; gastrointestinal tumors (GIT)) we aimed at identification of underlying molecular mechanisms. Using whole-genome sequencing, we focused on (I) shared and (II) mutually exclusive mutations and describe the process of ongoing mutational events in tumor-derived cell cultures. The landscape of MLH1<sup>&#8722;/&#8722;</sup> tumors is heterogeneous with only a few shared mutations being detectable among different tumor entities (<i>ARID1A</i> and <i>IDH2</i>). With respect to coding microsatellite analysis of MMR-D-related target genes, partial overlap was detectable, yet recognizing shared antigens. The present study is the first reporting results of a comparison between spontaneously developing tumors in MMR-D driven tumorigenesis. Additionally to identifying <i>ARID1A</i> as potential causative mutation hotspot, this comprehensive characterization of the mutational landscape may be a good starting point to refine therapeutic concepts.
ISSN:2072-6694